Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on CymaBay Therapeutics

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

CymaBay Therapeutics, formerly known as Metabolex, develops drugs to treat diabetes and related metabolic disorders. It plans to raise $84.5 million in a secondary public offering, as reported in the PharmSource Lead Sheet on July 20, 2017.

Corporate Highlights

  • CymaBay Therapeutics was incorporated in Delaware in October 1988 under the name Transtech Corporation.
  • Corporate Headquarters: Newark, CA – approximately 8,894 square feet of office and laboratory space
  • Stock Exchange: NASDAQ
  • Stock Symbol: CBAY

Sourcing Opportunities

  • CymaBay Therapeutics plans to use the proceeds to fund general corporate purposes and for the clinical development of seladelpar:
  • Seladelpar – To complete a Phase I clinical trial:
    • For treatment of NASH
    • Dosage Form: Capsule
    • Nature of API: Chemical – Normal potency
    • Therapeutic Areas: Immunomodulator; Liver disease; Antifibrotic
  • Seladelpar – To complete a Phase II clinical trial:
    • For treatment of primary biliary cholangitis
    • Dosage Form: Capsule
    • Nature of API: Chemical – Normal potency
    • Therapeutic Areas: Immunomodulator; Liver disease; Antifibrotic
  • The company contracts with contract research organizations (CROs) to conduct clinical trials.
  • CymaBay Therapeutics currently does not own or operate any manufacturing facilities and relies on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • CymaBay Therapeutics has no sales, marketing and distribution capabilities. The company may later enter strategic partnerships to commercialize approved product candidates.

Business Relationships

  • In December 2016, CymaBay Therapeutics and Kowa Pharmaceuticals America entered into an exclusive license agreement for the development and commercialization of arhalofenate in the US. Under the terms of the agreement, Kowa paid a $5 million upfront payment and up to $200 million in milestone payments.1

Drug Product Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
CB-001 Diabetes Unknown Preclinical TBA
MBX-2982 Type 2 diabetes Oral Phase I TBA
Seladelpar
(MBX-8025)
Non-alcoholic steatohepatitis/NASHs Oral – Solid Phase I TBA
Seladelpar
(MBX-8025)
Primary biliary cholangitis Capsule Phase II TBA
Arhalofenate Gout Oral – Solid Phase II To initiate a Phase III trial

Finances

(In $ thousands) 2016 2015
Revenues
R&D Expenditures
15,941
17,026
General & Administrative Expenditures
9,645
8,871
Total Operating Expenses
25,586
25,897

11CymaBay Therapeutics, Inc., 3/23/17 10-K, SEC.gov

Contact Information

CymaBay Therapeutics, Inc. Key Officers
7999 Gateway Blvd., Suite 130 Sujal Shah, Interim President & CEO
Newark, CA, 94545 USA Charles A. McWherter, PhD, CSO & SVP
Phone: +1-510-293-8800 Pol Boudes, MD, CMO
Web: http://www.cymabay.com Jiangao Song, Associate Director, Chemical Development

 

Related posts:
Follow the Money to Pharmaceutical Opportunities – Spotlight on AveXis, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on AmpliPhi Biosciences Corporation
Follow the Money to Pharmaceutical Opportunities – Spotlight on ContraVir Pharmaceuticals, Inc.

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu